2014 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/19/14Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients
Clovis’ “BRCAness” DNA signature predicts which patients respond to rucaparib therapy Overall response rate (ORR) of 70% in BRCA-mutant patients; responses observed in patients with both germline and somatic mutations ORR of 40% in patients with BRCAness signature (all BRCA wild-type) ORR of only 8% in patients without BRCAness signature (all BRCA wild-type) Approximately ... 
Printer Friendly VersionDownload PDF
11/18/14Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
67% objective response rate (ORR) observed in evaluable heavily-pretreated T790M+ patients treated with 625mg or 500mg BID (clinical dose group) Median PFS of 10.4 months in clinical dose group; data continue to mature Well-tolerated – majority of treatment-related adverse events are grade 1-2 In T790M-negative patients treated with 625mg or 500mg BID, 36% ORR and median PFS of... 
Printer Friendly VersionDownload PDF
11/17/14Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
Study to evaluate the combination of rociletinib (CO-1686) with trametinib for patients with advanced or metastatic mutant EGFR NSCLC BOULDER, Colo.--(BUSINESS WIRE)--Nov. 17, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). T... 
Printer Friendly VersionDownload PDF
11/12/14Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
Study to compare rociletinib (CO-1686) to standard-of-care erlotinib as treatment for patients with newly-diagnosed EGFR-mutant advanced non-small cell lung cancer (NSCLC) BOULDER, Colo.--(BUSINESS WIRE)--Nov. 12, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patien... 
Printer Friendly VersionDownload PDF
11/06/14Clovis Oncology Announces Third Quarter 2014 Operating Results
Data updates for rucaparib and rociletinib to be presented in oral presentations at the ENA Symposium November 20 and 21 $278.3 million raised in September sale of senior convertible notes Encouraging rucaparib data in ovarian cancer presented at ESMO First patients enrolled in lucitanib Phase 2 studies in breast cancer and squamous NSCLC Rociletinib (CO-1686) NDA and MAA submissions expected in mid-2015 BOULDER... 
Printer Friendly VersionDownload PDF
11/04/14Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Nov. 4, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s President and CEO, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, November 11, at 2:00pm MST. The conference is being held at the Arizona Biltmore in Phoenix, Arizona. A live webcast of the corporate presentation at the conference will be accessible through the investor relati... 
Printer Friendly VersionDownload PDF
10/23/14Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 23, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the Company’s oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial... 
Printer Friendly VersionDownload PDF
10/22/14Clovis Oncology to Announce Third Quarter 2014 Financial Results and Host Webcast Conference Call on November 6
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 22, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2014 financial results on Thursday, November 6, 2014, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
09/28/14Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy
Encouraging disease control rate of 93 percent, RECIST response rate of 71 percent observed in Phase 2 study of ovarian cancer patients with BRCA mutations; no drug discontinuations due to treatment-related adverse events 56 percent of non-mutant BRCA patients in the ARIEL2 study to date exhibit HRD and may benefit from rucaparib treatment Initial ARIEL2 clinical efficacy data to be presented in oral p... 
Printer Friendly VersionDownload PDF
09/10/14Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in FGF-aberrant Advanced Breast Cancer
BOULDER, Colo.--(BUSINESS WIRE)--Sep. 10, 2014-- Clovis Oncology (NASDAQ:CLVS) today announced that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site. Lucitanib is the Company’s oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 and 2 (FGFR1-2), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) an... 
Printer Friendly VersionDownload PDF
09/09/14Clovis Oncology Announces Exercise in Full by Initial Purchasers of Their Option to Purchase an Additional $37.5 Million Aggregate Principal Amount of the Company’s 2.50% Convertible Senior Notes Due 2021
BOULDER, Colo.--(BUSINESS WIRE)--Sep. 9, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the initial purchasers of the previously announced offering of the Company’s 2.50% Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to exercise in full their option to purchase an additional $37.5 million aggregate ... 
Printer Friendly Version 
09/08/14Clovis Oncology to Present at the 2014 Morgan Stanley Global Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Sep. 8, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s president and CEO, will present at the 2014 Morgan Stanley Global Healthcare Conference on Tuesday, September 9, at 4:05pm EST. The conference is being held at the Grand Hyatt in New York City. A live webcast of the corporate presentation at the conference will be accessible through the investor relati... 
Printer Friendly Version 
09/03/14Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes
BOULDER, Colo.--(BUSINESS WIRE)--Sep. 3, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of $250 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Clovis Oncology has also granted the initial purchasers a 30-day option to purchase up to $37.5 million aggregate principal amount... 
Printer Friendly VersionDownload PDF
09/02/14Clovis Oncology to Offer $200 Million of Convertible Senior Notes
BOULDER, Colo.--(BUSINESS WIRE)--Sep. 2, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of its convertible senior notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Clovis Oncology also expects to grant the initial purchasers a 30-day o... 
Printer Friendly VersionDownload PDF
08/07/14Clovis Oncology Announces Second Quarter 2014 Operating Results
CO-1686 NDA submission expected by mid-2015 CO-1686 Breakthrough Therapy designation granted during Q2 Proposed INN rociletinib assigned to CO-1686 Rociletinib and rucaparib data updates to be presented at medical conferences in Fall 2014 BOULDER, Colo.--(BUSINESS WIRE)--Aug. 7, 2014-- Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its second quarter ended June 30, 2014, and provided a... 
Printer Friendly VersionDownload PDF
07/21/14Clovis Oncology to Announce Second Quarter 2014 Financial Results and Host Webcast Conference Call on August 7
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 21, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its second quarter 2014 financial results on Thursday, August 7, 2014, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
06/23/14Clovis Oncology Announces First Patient Enrolled in TIGER2 Study
Study to evaluate CO-1686 as treatment for second-line mutant EGFR NSCLC patients with confirmed T790M resistance mutation BOULDER, Colo.--(BUSINESS WIRE)--Jun. 23, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor ... 
Printer Friendly VersionDownload PDF
06/16/14Clovis Oncology Announces First Patient Enrolled in RUCAPANC Study
Study to evaluate PARP inhibitor rucaparib as treatment for locally advanced or metastatic pancreatic cancer with a deleterious BRCA mutation BOULDER, Colo.--(BUSINESS WIRE)--Jun. 16, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the RUCAPANC (Rucaparib Assessment in BRCA-mutated Pancreatic Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rucaparib is the Company’s oral, potent, small molecule ... 
Printer Friendly VersionDownload PDF
05/31/14Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1/2 Study Results in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
58% objective response rate observed to date in 40 evaluable heavily-pretreated T790M+ patients in Phase 1 and early Phase 2 expansion cohorts Current estimate of median PFS greater than 12 months in T790M+ patient population; observed median not yet reached Well-tolerated – majority of treatment-related adverse events are grade 1-2 and manageable Only TKI to completely spare wild-type ... 
Printer Friendly VersionDownload PDF
05/31/14Clovis Oncology Announces Encouraging Data from Phase 1/2a Study Evaluating Lucitanib in Advanced Solid Tumors
Durable clinical responses observed in patients with both FGF-aberrant and angiogenic-sensitive tumor types In heavily-pretreated FGF-aberrant breast cancer patients, a 50 percent objective response rate and 9.6 months progression-free survival were observed Most drug-related adverse events were mild or asymptomatic and relate to on-target VEGFR2 inhibition Unique inhibitor of three dif... 
Printer Friendly VersionDownload PDF
05/31/14Clovis Oncology’s Phase 1 Study of Rucaparib Demonstrates Compelling Clinical Activity and Safety in Patients with Solid Tumors
After 24 weeks of rucaparib monotherapy, 82 percent disease control rate observed in ovarian cancer patients with BRCA mutations No drug discontinuations because of treatment-related adverse events in Phase 1 study Rucaparib at recommended Phase 2 dose of 600 mg BID showed strong activity with good tolerability Now enrolling ARIEL2 and ARIEL3 studies in patients with platinum-sensitive ... 
Printer Friendly VersionDownload PDF
05/19/14Clovis Oncology Receives Breakthrough Therapy Designation for CO-1686 for the Treatment of Second-line EGFR Mutant Non-small Cell Lung Cancer (NSCLC) in Patients with the T790M Mutation
BOULDER, Colo.--(BUSINESS WIRE)--May 19, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Company’s investigational agent CO-1686 as monotherapy for the treatment of second-line EGFR mutant NSCLC in patients with the T790M mutation. The Breakthrough Therapy designation was granted based on interim efficacy and safety results from an ongoing ... 
Printer Friendly VersionDownload PDF
05/14/14Clovis Oncology Announces Clinical Data to Be Presented at 2014 ASCO Annual Meeting
Abstracts provide updates on the Company’s three investigational therapies in development: - CO-1686, an oral, novel mutant EGFR inhibitor for non-small cell lung cancer (NSCLC) - Rucaparib, an oral PARP inhibitor for ovarian cancer, and - Lucitanib, an oral tyrosine-kinase inhibitor for breast cancer and squamous NSCLC BOULDER, Colo.--(BUSINESS WIRE)--May 14, 2014-- Clovis Oncology (NASDAQ:CLVS) announced that five a... 
Printer Friendly VersionDownload PDF
05/08/14Clovis Oncology Announces First Quarter 2014 Operating Results
Encouraging CO-1686 clinical activity and progression-free survival (PFS) in non-small cell lung cancer (NSCLC) reported at European Lung Cancer Conference in late March; CO-1686 Phase 2 expansion cohorts enrolling TIGER1 and TIGER2 studies to initiate shortly CO-1686 New Drug Application (NDA) submission planned by mid-2015 Clovis to present updated data on its pipeline products... 
Printer Friendly VersionDownload PDF
04/28/14Clovis Oncology to Announce First Quarter 2014 Financial Results and Host Webcast Conference Call on May 8
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 28, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its first quarter 2014 financial results on Thursday, May 8, 2014, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on Thursday, May 8, at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovi... 
Printer Friendly VersionDownload PDF
04/03/14Foundation Medicine and Clovis Oncology Expand Collaboration to Develop Novel Companion Diagnostic for Rucaparib in Ovarian Cancer
Companion diagnostic development builds upon regulatory strategy for Foundation Medicine’s comprehensive genomic profiling platform and differentiated clinical development strategy for Clovis Oncology CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ: FMI) and Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the expansion of their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a n... 
Printer Friendly VersionDownload PDF
03/27/14Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC)
64% objective response rate observed in T790M+ patients PFS greater than six months in heavily-pretreated T790M+ patient population; median not yet reached Well-tolerated – only one of 62 patients treated at therapeutic doses of CO-1686 discontinued because of adverse events Only TKI to completely spare wild-type EGFR signaling GENEVA--(BUSINESS WIRE)--Mar. 27, 2014-- Clovis Onc... 
Printer Friendly VersionDownload PDF
02/27/14Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program
CO-1686 Phase 2 expansion cohorts increased in size to approximately 300 patients Potential to accelerate NDA submission timeline BOULDER, Colo.--(BUSINESS WIRE)--Feb. 27, 2014-- Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter and year ended December 31, 2013, and provided an update on the expected milestones for its clinical development programs for 2014. “2013 w... 
Printer Friendly VersionDownload PDF
02/18/14Clovis Oncology to Announce Fourth Quarter/Year End 2013 Financial Results and Host Webcast Conference Call on February 27
BOULDER, Colo., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Clovis Oncology, Inc. (Nasdaq:CLVS) will announce its fourth quarter/year end 2013 financial results on Thursday, February 27, 2014, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast on Thursday, February 27, at 4:30 p.m. ET to discuss the company's results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at ww... 
Printer Friendly VersionDownload PDF
02/06/14Clovis Oncology to Present at the 2014 Leerink Global Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 6, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s president and CEO, will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, at 11:25am MST. The conference is being held at the Waldorf Astoria in New York City. A live webcast of the corporate presentation at the conference will be accessible through the investor relatio... 
Printer Friendly VersionDownload PDF
01/13/14Clovis Oncology Announces 2014 Objectives and Financial Guidance
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 13, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced anticipated development milestones and financial guidance for 2014. Clovis currently has three clinical development programs underway, and expects to initiate four registration studies for two of its programs during the first half of 2014. “2014 promises to be a defining year for Clovis Oncology,” said Patrick J. Mahaffy, President and CEO... 
Printer Friendly VersionDownload PDF
01/06/14Clovis Oncology to Present at the 32nd Annual J.P. Morgan Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 6, 2014-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 3:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast of the presentation can be accessed through the investor relat... 
Printer Friendly VersionDownload PDF
Investor Relations and Corporate Communications Contacts
Breanna Burkart
Phone: 303.625.5023
E-mail: bburkart@clovisoncology.com
Anna Sussman
Phone: 303.625.5022
E-mail: asussman@clovisoncology.com